Nicole Cobo, MD
Neurology with Special Qualifications in Child Neurology · Long Beach, CANPI 1497954119
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.4%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 55 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 27.4% of the total. Among neurology with special qualifications in child neurology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 690 payments — averaging $47.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$9K
- UCB, Inc.$6K
- UCB Biosciences Inc.$6K
- AbbVie$1K
- SK Life Science, Inc.$1K
- Neurelis, Inc.$950
- plus $8K from 49 others
Across 27 payments — averaging $9397.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$172K
- Jazz Pharmaceuticals Inc.$48K
- UCB Biosciences Inc.$34K
What the payments were for
- Consulting fees$8,19025%
- Speaking & faculty fees$7,16022%
- Food & beverage$16,69251%
- Education$4591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$32,501 in reported general payments places this provider in the 90th percentile of 216 neurology with special qualifications in child neurology providers in California.
See all neurology with special qualifications in child neurology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 17 | $131,460 |
| XcopriCenobamate | 73 | $105,829 |
| FinteplaFenfluramine Hcl | 13 | $105,110 |
| BriviactBrivaracetam | 15 | $32,849 |
| OnfiClobazam | 13 | $20,401 |
| LamictalLamotrigine | 22 | $13,386 |
| Rufinamide | 13 | $12,633 |
| Lacosamide | 20 | $10,589 |
| Clobazam | 20 | $5,837 |
| Oxcarbazepine | 13 | $1,578 |
| Scopolamine | 12 | $920 |
| Levetiracetam | 16 | $453 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 17 | $430 |
| Trazodone Hcl | 23 | $303 |
| Tizanidine Hcl | 18 | $190 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Fintepla, Briviact | $6,305 | $137,95928 claims |
| SK Life Science, Inc.Xcopri | $1,345 | $105,82973 claims |
| Lundbeck LLCOnfi | $359 | $20,40113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 216 neurology with special qualifications in child neurology providers in California.
Other neurology with special qualifications in child neurology in Long Beach
- Perry LubensLong Beach$8K
- Michael ChezSacramento$374K
- Allen BottOakland$372K
- Joseph SullivanSan Francisco$240K
- Ann SegerenStanford$172K
- Rajsekar RajaramanLos Angeles$134K
- Deborah HolderLos Angeles$130K
- Akash VirupakshaiahSan Francisco$94K
- Brittany PassiakSan Diego$90K
- Kevin ShapiroMadera$84K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.